News / Health

'Serial Killer' Cells Demolish Leukemia Tumors

Test patients show complete remission or significant improvement

This microscopy image provided by Dr. Carl June on Wednesday, Aug. 10, 2011 shows immune system T-cells, center, binding to beads which cause the cells to divide. The beads, depicted in yellow, are later removed, leaving pure T-cells which are then ready
This microscopy image provided by Dr. Carl June on Wednesday, Aug. 10, 2011 shows immune system T-cells, center, binding to beads which cause the cells to divide. The beads, depicted in yellow, are later removed, leaving pure T-cells which are then ready

Multimedia

Audio
Jessica Berman

U.S. researchers say they've been able to modify a patient's immune system T cells, turning them into “serial killer” cells which zero in on cancer and obliterate it.

It’s being called a breakthrough in the treatment of a form of leukemia, a hard to treat and usually fatal blood cancer.  

Chronic lymphocytic leukemia (CLL) is marked by a slow increase in immune system white blood cells, called B lymphocytes. These B cells, as they're known, are manufactured by the bone marrow, the spongy tissue inside bones that also manufactures red blood cells.

Eventually, the healthy blood cells are crowded out by the proliferating B cells, the patient experiences bone marrow failure, and - without a bone marrow transplant - dies.

A transplant of healthy bone marrow from a donor has been the only treatment and potential cure for chronic lymphocytic leukemia. But it is very difficult to find a match and many people with CLL die while waiting. Even with a transplant, experts say only about half of CLL patients survive the procedure.

Three CLL patients who had run out of treatment options were selected for an experiment at the University of Pennsylvania. Researchers genetically engineered another one of their immune system cells, the T lymphocytes, to attack cancerous B cells.

Carl June, a professor of pathology and laboratory medicine at the school’s Abramson Cancer Center, was the study’s lead author.  

“The actual trial exceeded our wildest outcome and imagination actually," says Carl June, professor of pathology and laboratory medicine, who was the study’s lead author, "because what we found is all three patients have had a remarkable anti-tumor response and that literally pounds of leukemia have been eradicated in all three patients.”

Two of the three CLL patients had a complete remission of their disease and there was a significant improvement in the third.

Watch related video story by Vidushi Sinha

The T cells were genetically modified using a harmless virus, which carried an anti-body called a chimeric antigen receptor (CAR). Antibodies are immune system proteins which are produced in response to an infection.  

The CAR was engineered to bind to another protein called CD19 that’s present on the surface of normal B lymphocytes and all CLL tumor cells.  

Scientists say the modified T cells, injected into the patients following standard chemotherapy, homed in on the cancerous B cells inside the bone marrow, each T lymphocyte killing thousands of tumor cells.  

Researcher Michael Kalos says the team also engineered a signaling molecule that binds to CD19, triggering the continued production of thousands of T cells. The genetically engineered cells act as sentries against cancerous B cells should they return.

“We saw a substantial number of cells remaining circulating and in the marrow of patients very, very late after infusion, nine to 12 months, entirely unprecedented in the field," says Kalos. "And finally we saw that those cells, not only did they remain there, but they were able to be triggered, recognize and kill cancer cells when they encountered them again.”

In a report describing the so-called “serial killer” T cell therapy in the New England Journal of Medicine, researchers say it completely obliterated cancer cells in a 64-year-old man with CLL three weeks after treatment, and three to six months later, researchers could detect no sign of disease.

The patient’s marrow began manufacturing healthy B cells to replace the ones that were destroyed as "collateral damage" by the therapy. Cells that did not express CD19 were unaffected.


You May Like

US Firms Concerned About China's New Cyber Regulations

New rules would require technology companies doing business in financial sector to hand over their source code, adopt Chinese encryption algorithms More

WHO Focus on Ebola Shifts to Ending Outbreak

Focus to be less on building facilities and more on efforts to find infected people, manage their cases, engage with communities and ensure proper burials More

US Scientist Who Conceived of Groundbreaking Laser Technology Dies

Charles Townes, Nobel laureate, laser co-creator paved way for other scientific discoveries: CDs, eye surgery, metal cutters to name a few technologies that rely on lasers More

This forum has been closed.
Comments
     
There are no comments in this forum. Be first and add one

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Super Bowl Ads Compete for Eyes on TV, Webi
X
January 29, 2015 9:58 AM
Super Bowl Sunday (Feb. 1) is about more than just the NFL's American football championship and big parties to watch the game. Viewers also tune in for the world famous commercials that send Facebook and Twitter abuzz. Daniela Schrier reports on the social media rewards for America’s priciest advertising.
Video

Video Super Bowl Ads Compete for Eyes on TV, Web

Super Bowl Sunday (Feb. 1) is about more than just the NFL's American football championship and big parties to watch the game. Viewers also tune in for the world famous commercials that send Facebook and Twitter abuzz. Daniela Schrier reports on the social media rewards for America’s priciest advertising.
Video

Video Theologians Cast Doubt on Morality of Drone Strikes

In 2006, stirred by photos of U.S. soldiers mistreating Iraqi prisoners, a group of American faith leaders and academics launched the National Religious Campaign Against Torture. It played an important role in getting Congress to investigate, and the president to ban, torture. VOA's Jerome Socolovsky reports.
Video

Video Freedom on Decline Worldwide, Report Says

The state of global freedom declined for the ninth consecutive year in 2014, according to global watchdog Freedom House's annual report released Wednesday. VOA's William Gallo has more.
Video

Video As Ground Shifts, Obama Reviews Middle East Strategy

The death of Saudi Arabia’s king, the collapse of a U.S.-friendly government in Yemen and a problematic relationship with Israel’s leadership are presenting a new set of complications for the Obama administration and its Middle East policy. Not only is the U.S. leader dealing with adversaries in Iran, the Islamic State and al-Qaida, but he is now juggling trouble with traditional allies, as White House correspondent Luis Ramirez reports.
Video

Video MRI Seems to Help Diagnose Prostate Cancer, Preliminary Study Shows

Just as with mammography used to detect breast cancer, there's a lot of controversy about tests used to diagnose prostate cancer. Fortunately, a new study shows doctors may now have a more reliable way to diagnose prostate cancer for high risk patients. More from VOA's Carol Pearson.
Video

Video Smartphones About to Make Leap, Carry Basic Senses

Long-distance communication contains mostly sounds and pictures - for now. But scientists in Britain say they are close to creating additions for our smartphones that will make it possible to send taste, smell and even a basic touch. VOA’s George Putic reports.
Video

Video NASA Monitors Earth’s Vital Signs From Space

The U.S. space agency, NASA, is wrapping up its busiest 12-month period in more than a decade, with three missions launched in 2014 and two this month, one in early January and the fifth scheduled for January 29. As VOA’s Rosanne Skirble reports, the instruments being lifted into orbit are focused on Earth’s vital life support systems and how they are responding to a warmer planet.
Video

Video Saved By a Mistake - an Auschwitz Survivor's Story

Dagmar Lieblova was 14 when she arrived at Auschwitz in December 1943, along with her entire Czech Jewish family. All of them were to die there, but she was able to leave after several months due to a bureaucratic mix-up which saved her life. Now 85, with three children and six grandchildren, she says she has a feeling of victory. This report by Ahmad Wadiei and Farin Assemi, of RFE/RL's Radio Farda is narrated by RFE’s Raymond Furlong.

Circumventing Censorship

An Internet Primer for Healthy Web Habits

As surveillance and censoring technologies advance, so, too, do new tools for your computer or mobile device that help protect your privacy and break through Internet censorship.
More

All About America

AppleAndroid